In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selected Start-Ups Founded in 2000 (0002)

Executive Summary

{In Vivo} summarizes the technologies of several medical companies founded recently, including Belgium's [AlgoNomics NV], a new entrant in the biocomputing and bioinformatics arena. [CoPharma Inc.]'s mission is to develop drug and biological products through joint ventures with discovery firms. Launched in February 2000 with $2 million from Sanderling, Alta Partners and Graystone, [Cythera Inc.] will develop therapies based on the transplantation of functional human cells grown{ in vitro}, offering an alternative to the use of donated human tissues. [Embolic Protection Inc.] has developed a device, consisting of a guide wire and filter mechanism, to remove embolic debris. Denmark's [NsGene A/S] is a joint venture of NeuroSearch A/S and the University of Lund. [WebEBM] will offer evidence-based clinical guidelines for 400 diseases or conditions on its website.

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel